Evofem Biosciences, Inc. Stock News

— Pharma 1 Targets Mid-2025 Regulatory Submission in UAE for SOLOSEC to Treat Bacterial Vaginosis and Trichomoniasis — SAN DIEGO , May 21, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) and private Emirati health care company Pharma 1 Drug Store LLC have signed a License and Supply Agreement for the Middle East rights to SOLOSEC® (secnidazole) 2 g oral gran...

SAN DIEGO , May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter ended March 31, 2025. "Quarterly fluctuations are normal for our business, which is why we focus on driving annual growth," said Saundra Pelletier, Evofem's CEO.

SAN DIEGO , April 14, 2025 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that members of its management team will present at the upcoming Emerging Growth Conference as follows: Date:                      Thursday, April 17, 2025 Time:                    10:50 – 11:20 am ET (7:50 – 8:20 am PT) Live webcast:          https://evofem.investorroom.com/EmergingGrowth2025 or ...

-- Evofem's Cost to Manufacture PHEXXI will Decrease by 55% - 60% -- SAN DIEGO , March 26, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply Agreement (L&S Agreement) with Windtree Therapeutics, Inc. (NasdaqCM: WINT), under which Windtree will be Evofem's sourcing partner for PHEXXI® (lactic acid, ci...

-- 2024 Net Sales Increased 6% to $19.4 Million  -- -- Total Operating Expense Reduced 27% from 2023 Levels,  Excluding Non-cash Amortization Expense  -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO , March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosci...

WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, is pleased to announce that it has entered into a License and Supply Agreement to become the sourcing ...

-- Allowed Patent Extends SOLOSEC IP to 2040 with  Broad Claims that are Orange Book-listable -- SAN DIEGO , Feb. 13, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 17/028,838, entitled "Method and Pharmaceutical Composition for Treating or P...